About InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Zolbetuximab making it ideal for research use. This Zolbetuximab biosimilar antibody reacts with isoform 2 of human claudin 18. Claudin 18.2, a member of the claudin family, is commonly expressed in multiple cancers, including gastric and pancreatic cancer. Claudin 18.2 is not expressed in any healthy tissues except for gastric mucosa. Claudins play a major role in tight junctions which establish the paracellular barrier that controls the flow of molecules in the intercellular space between the cells of an epithelium. They also play an important role in tumorigenesis and inflammation. Alterations in claudin expression have been shown to lead to impaired functions of tight junctions, influence signaling pathways, and act as tumor promoting events in some epithelial cancers. In a humanized mouse model of prostate cancer Zolbetuximab demonstrated antitumor activity by stimulating ADCC and/or CDC. InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman claudin 18.2 Reported ApplicationsFunctional assays FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
